Functional Engagement of the PD-1/PD-L1 Complex But Not PD-L1 Expression Is Highly Predictive of Patient Response to Immunotherapy in Non-Small-Cell Lung Cancer.
Lissete Sánchez-MagranerJuan GumuzioJames MilesNicole QuimiPurificación Martínez Del PradoMaría Teresa Abad-VillarFernando PikabeaLaura OrtegaMaría C EtxezarragaSalvador Martín-AlgarraMaría D LozanoMónica Saiz-CaminMikel Egurrola-IzquierdoInmaculada Barredo-SantamaríaAlberto Saiz-LópezJenifer Gomez-MediavillaNerea Segues-MerinoMaría Aranzazu Juaristi-AbaunzAnder UrruticoecheaErica J GeraedtsKim van ElstNiels J M ClaessensAntoine ItalianoChristopher J ApplebeeSandra Del CastilloCharles EvansFernando AguirrePeter J ParkerVéronique CallejaPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
The functional readout of PD-1/PD-L1 interaction as a predictive biomarker for the stratification of patients with non-small-cell lung carcinoma, combined with PD-L1 expression, should significantly improve the response rates to immunotherapy. This would both capture patients excluded from checkpoint immunotherapy (high PD-1/PD-L1 interaction but low PD-L1 expression, 24% of patients) and additionally avoid treating patients who despite their high PD-L1 expression do not respond and suffer from side effects.